Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)

NCT04631016 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04631016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04631016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2020
Completion date
November 13, 2023
Enrollment
137 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

chronic bronchitis, chronic obstructive pulmonary disease (copd)